333 related articles for article (PubMed ID: 21463652)
1. Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
[TBL] [Abstract][Full Text] [Related]
2. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
[TBL] [Abstract][Full Text] [Related]
3. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
[TBL] [Abstract][Full Text] [Related]
4. Cognitive enhancers: focus on modulatory signaling influencing memory consolidation.
Roesler R; Schröder N
Pharmacol Biochem Behav; 2011 Aug; 99(2):155-63. PubMed ID: 21236291
[TBL] [Abstract][Full Text] [Related]
5. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
Terry AV; Buccafusco JJ; Wilson C
Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
[TBL] [Abstract][Full Text] [Related]
6. 5-HT(7) receptors in the modulation of cognitive processes.
Cifariello A; Pompili A; Gasbarri A
Behav Brain Res; 2008 Dec; 195(1):171-9. PubMed ID: 18243350
[TBL] [Abstract][Full Text] [Related]
7. Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and gamma-aminobutyric acid systems.
Miczek KA; Fish EW; De Bold JF; De Almeida RM
Psychopharmacology (Berl); 2002 Oct; 163(3-4):434-58. PubMed ID: 12373445
[TBL] [Abstract][Full Text] [Related]
8. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
[TBL] [Abstract][Full Text] [Related]
9. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
[TBL] [Abstract][Full Text] [Related]
10. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
11. On the trail of a cognitive enhancer for the treatment of schizophrenia.
Stip E; Chouinard S; Boulay LJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
[TBL] [Abstract][Full Text] [Related]
12. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
Karasawa J; Hashimoto K; Chaki S
Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
[TBL] [Abstract][Full Text] [Related]
13. AMPA receptor potentiators as cognitive enhancers.
O'Neill MJ; Dix S
IDrugs; 2007 Mar; 10(3):185-92. PubMed ID: 17351873
[TBL] [Abstract][Full Text] [Related]
14. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.
Wallace TL; Porter RH
Biochem Pharmacol; 2011 Oct; 82(8):891-903. PubMed ID: 21741954
[TBL] [Abstract][Full Text] [Related]
15. 5-HT(6) receptor and cognition.
Codony X; Vela JM; Ramírez MJ
Curr Opin Pharmacol; 2011 Feb; 11(1):94-100. PubMed ID: 21330210
[TBL] [Abstract][Full Text] [Related]
16. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
Witkin JM; Nelson DL
Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
[TBL] [Abstract][Full Text] [Related]
17. The role of 5-HT(1A) receptors in learning and memory.
Ogren SO; Eriksson TM; Elvander-Tottie E; D'Addario C; Ekström JC; Svenningsson P; Meister B; Kehr J; Stiedl O
Behav Brain Res; 2008 Dec; 195(1):54-77. PubMed ID: 18394726
[TBL] [Abstract][Full Text] [Related]
18. The effect of cholinergic, GABAergic, serotonergic, and glutamatergic receptor modulation on posttrial memory processing in the hippocampus.
Farr SA; Flood JF; Morley JE
Neurobiol Learn Mem; 2000 Mar; 73(2):150-67. PubMed ID: 10704325
[TBL] [Abstract][Full Text] [Related]
19. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
20. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function.
Fone KC
Neuropharmacology; 2008 Nov; 55(6):1015-22. PubMed ID: 18655798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
